LIPA and metabolic dysfunction-associated steatotic liver disease: ADRP can target adenosine monophosphate-activated protein kinase alpha (AMPKα)-dependent lipophagy, mediated by the Perilipin 2-lysosomal acid lipase (PLIN2-LIPA) axis which ameliorates NAFLD (Fang et al., 2024).